Area of research
Surgery · Endocrinology, Diabetes and Metabolism
Research interest
Research focused on Evolocumab and PCSK9, with related work in Statin, Hazard ratio, Type 2 diabetes. Notable publications include 'Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease', '2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk', and 'EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update'.
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Cognition After Lowering LDL-Cholesterol With Evolocumab
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease
Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation
Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Cognitive Function in a Randomized Trial of Evolocumab
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin
A Missense Variant in PLEC Increases Risk of Atrial Fibrillation
Design and rationale of the <scp>EBBINGHAUS</scp> trial: A phase 3, double‐blind, placebo‐controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid‐lowering therapy—A cognitive study of patients enrolled in the <scp>FOURIER</scp> trial
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials